Cardiol Therapeutics Inc.

Investor FAQ

Answers to frequently asked questions about Cardiol Therapeutics Inc. (TSX:CRDL).

  1. Latest News?

    Cardiol Therapeutics announced on January 17, 2023, that the first patient has been enrolled in a Phase II study evaluating CardiolRx™ for the treatment of recurrent pericarditis. The study aims to assess the drug's tolerance, safety, and efficacy, with a total enrollment of 25 patients at specialized clinical centers in the U.S.

  2. Clinical Trials

    Cardiol Therapeutics is currently conducting a Phase II open-label pilot study (NCT05494788) to evaluate CardiolRx™ in patients with recurrent pericarditis. The study will measure changes in patient-reported pain and other clinical markers over an 8-week period, with secondary endpoints assessed after 26 weeks of treatment.